Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017

Adam J. Rose*, Jaclyn M.W. Hughto, Michael S. Dunbar, Emily K. Quinn, Madeline Deutsch, Jamie Feldman, Asa Radix, Joshua D. Safer, Jillian C. Shipherd, Julie Thompson, Guneet K. Jasuja

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Combination therapy with estrogen and spironolactone may help some transgender women achieve desired results. We used two databases, OptumLabs® Data Warehouse (OLDW) and Veterans Health Administration (VHA), to examine trends in feminizing therapy. We included 3368 transgender patients from OLDW and 3527 from VHA, all of whom received estrogen, spironolactone, or both between 2006 and 2017. In OLDW, the proportion receiving combination therapy increased from 47% to 75% during this period. Similarly, in VHA, the proportion increased from 39% to 69% during this period. We conclude that the use of combination hormone therapy has become much more common over the past decade.

Original languageAmerican English
Pages (from-to)188-194
Number of pages7
JournalTransgender Health
Issue number2
StatePublished - 1 Apr 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023, Mary Ann Liebert, Inc.


  • aldosterone antagonists
  • drug therapy
  • hormones
  • transgender persons


Dive into the research topics of 'Trends in Feminizing Hormone Therapy for Transgender Patients, 2006-2017'. Together they form a unique fingerprint.

Cite this